💰FDA Announces Animal Drug User Fee Rates for FY 2026
The Food and Drug Administration (FDA, the Agency, or we) is announcing the fee rates and payment procedures for fiscal year (FY) 2026 animal drug user fees. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Animal Drug User Fee Amendments of 2023 (ADUFA V), authorizes FDA to collect user fees for certain animal drug applications and supplemental animal drug applications, for certain animal drug products, for certain establishments where such products are made, and for certain sponsors of such animal drug applications and/or investigational animal drug submissions. This notice establishes the fee rates for FY 2026.
Learn More📅Amended Notice of Meeting for National Advisory Child Health Council
The Department of Health and Human Services announces a change in the schedule for the National Advisory Child Health and Human Development Council meeting. The meeting will now occur from September 9 to September 10, 2025, with partial public closure. This notice serves to inform stakeholders about the adjusted timing of a significant health-related advisory session.
Learn More💰NIH Grant Evaluation Meetings for Biomedical Research Opportunities
The Department of Health and Human Services provides notice of closed meetings by the Center for Scientific Review, where various grant applications related to health and biomedical research will be evaluated. These meetings serve as a critical opportunity for stakeholders to gain insights and potential funding in the scientific community.
Learn More🏥Notice of Meeting Change for National Institute on Deafness Advisory Council
The Department of Health and Human Services announces a change in the meeting schedule for the National Deafness and Other Communication Disorders Advisory Council. The meeting will occur from September 4 to September 5, 2025, at the National Institutes of Health in Rockville, MD, with specific times for public accessibility.
Learn More🍽️FDA Announces Food Additive Petition for Medical Food
The Food and Drug Administration (FDA or we) is announcing that we have filed a food additive petition, submitted by the Spoonbill Foundation, proposing that we amend our food additive regulations to provide for the safe use of 4'-phosphopantetheine (4'-PPT) as a nutrient in medical food.
Learn More📄FDA Information Collection Approvals and Business Implications
The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.
Learn More💵NIH Notice of Closed Meetings Regarding Grant Evaluations
The Department of Health and Human Services announces closed meetings of the Center for Scientific Review to evaluate contract and grant proposals related to antimicrobial activity and neuroscience research. These meetings will contribute to discussions concerning confidential trade secrets and will take place virtually, adhering to privacy regulations.
Learn More🧬National Institute on Aging Meeting and Grant Review Notice
The Department of Health and Human Services announces a closed meeting of the National Institute on Aging's Board of Scientific Counselors to review individual grant applications. This meeting, restricted to public access, aims to discuss personnel qualifications and grant evaluations. Relevant security protocols for visitor access to NIH facilities are also outlined.
Learn More❌NIH Announces Cancellation of Program Projects Panel Meeting
The Department of Health and Human Services announces the cancellation of the Center for Scientific Review Special Emphasis Panel meeting scheduled for August 12, 2025. The cancellation is due to the re-assignment of program project applications, as detailed in the published Federal Register.
Learn More🏥Notice of NIDDK Meeting on Grant Evaluations and Funding
The Department of Health and Human Services announces a public meeting of the Board of Scientific Counselors at the National Institutes of Health to review and discuss grant applications and investigator qualifications related to diabetes and kidney diseases. The meeting includes an open and closed session, detailing agendas and accessibility provisions for attendees.
Learn More